This finding underscores the therapeutic promise of coupling a PRMT5 inhibitor such as LLY-283 with a FLT3 TKI, potentially offering a more effective strategy to target and eradicate FLT3-ITD AML stem cells. This evidence concerns the gene FLT3 and acute myeloid leukemia.